Mark Kaminski
YOU?
Author Swipe
View article: NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023 Open
Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to…
View article: Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma Open
Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a complete…
View article: A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 Open
Peer Reviewed
View article: Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last s…
View article: Supplementary Table S1 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Supplementary Table S1 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Supplementary Table S1 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 54K, Supplementary Table 2: Distribution of Risk Groups in Intergroup Trial S0016 and in Selected Other Recent Major Trials of Advanced Follicular Lymphoma
View article: Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 82K, Supplementary Figure 1: Wald Chi Square Analysis Defining Optimal Cutpoints for Lactate Dehydrogenase and Beta 2 Microglobulin Levels for Prognostic Model construction for PFS (S1A) or OS (S1B) for Patients Enrolled on Protoc…
View article: Data from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Data from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
Purpose: There is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial comparing six cycles of CHOP-R (cyclophosphamide–Adriamycin–vincristine–predni…
View article: Supplementary Figures 1-12 and Tables S1-S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Supplementary Figures 1-12 and Tables S1-S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Fig. S1: BTK mutations detected in cDNA in five FL BTK mutant cases. Fig. S2:BTK mutations destabilize the mutant BTK proteins. Fig. S3:BTK mutations do not influence PLCγ2-1217 phosphorylation in reconstituted lymphoma cell lines. Fig. S…
View article: Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Supplementary Figures S1-S5 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Figures 1-12 and Tables S1-S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Supplementary Figures 1-12 and Tables S1-S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Fig. S1: BTK mutations detected in cDNA in five FL BTK mutant cases. Fig. S2:BTK mutations destabilize the mutant BTK proteins. Fig. S3:BTK mutations do not influence PLCγ2-1217 phosphorylation in reconstituted lymphoma cell lines. Fig. S…
View article: Supplementary Data Table S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Supplementary Data Table S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Results from IP-mass spec of HA-BTK WT and two HA-BTK mutants and a control (BTK-/- reconstituted with empty vector FG9) and embedded VENN diagram
View article: Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Purpose:On the basis of the recent discovery of mutations in Bruton tyrosine kinase (BTK) in follicular lymphoma, we studied their functional properties.Experimental Design:We identified novel somatic BTK mutations in 7% of a combined tota…
View article: Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 54K, Supplementary Table 2: Distribution of Risk Groups in Intergroup Trial S0016 and in Selected Other Recent Major Trials of Advanced Follicular Lymphoma
View article: Data from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Data from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Purpose: The chromosomal deletion 11q affects biology and clinical outcome in chronic lymphocytic leukemia (CLL) but del11q-deregulated genes remain incompletely characterized.Experimental Design: We have employed integrated genomic profil…
View article: Supplementary Table 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Table 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 54K, Supplementary Table 1: Results of Multivariable Model of All Statistically Significant Factors for Both PFS and OS from Univariate Analyses
View article: Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Purpose:On the basis of the recent discovery of mutations in Bruton tyrosine kinase (BTK) in follicular lymphoma, we studied their functional properties.Experimental Design:We identified novel somatic BTK mutations in 7% of a combined tota…
View article: Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 82K, Supplementary Figure 1: Wald Chi Square Analysis Defining Optimal Cutpoints for Lactate Dehydrogenase and Beta 2 Microglobulin Levels for Prognostic Model construction for PFS (S1A) or OS (S1B) for Patients Enrolled on Protoc…
View article: Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Methods, Supplementary Figures 1-2, Supplementary Tables 1-4 from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Supplementary Methods, Supplementary Figures 1-2, Supplementary Tables 1-4 from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Open
Table S1. Yeast strains; Table S2. Primers used for yeasts mutagenesis; Table S3: B-factor for GTP/GDP during MD simulations with WT RRAGC or with point Mutations; Table S4: Energy contribution of each residue (kcal/mol) to GTP and GDP bin…
View article: Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Supplementary Table S2 from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Data from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Data from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Open
Purpose: This study was performed to further our understanding of the biological and genetic basis of follicular lymphoma and to identify potential novel therapy targets.Experimental Design: We analyzed previously generated whole exome seq…
View article: Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia Open
Related CCR Translation from A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia
View article: Supplementary Data Table S1 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Supplementary Data Table S1 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Mutations and associated characteristics of 10 FL cases with BTK mutations
View article: Supplementary Table 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Supplementary Table 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
PDF file 54K, Supplementary Table 1: Results of Multivariable Model of All Statistically Significant Factors for Both PFS and OS from Univariate Analyses
View article: Data from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Data from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Open
Purpose: This study was performed to further our understanding of the biological and genetic basis of follicular lymphoma and to identify potential novel therapy targets.Experimental Design: We analyzed previously generated whole exome seq…
View article: Data from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Data from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab Open
Purpose: There is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial comparing six cycles of CHOP-R (cyclophosphamide–Adriamycin–vincristine–predni…
View article: Supplementary Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Supplementary Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation Open
Supplementary Figure and Table legends